[외부감사 진단] 녹십자, 밸류 '575억' 관계사 큐레보에 순익 출렁

The reclassification of Curevo to FVPL assets means GC Biopharma's net profit is now highly sensitive to the clinical success and valuation of its US affiliate. This shift highlights a trend where biotech R&D milestones directly drive parent company earnings volatility, making the upcoming CRV-101 Phase 2 results a critical financial catalyst.